Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H2 2018
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2018'; Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Serine/threonine-protein kinase PLK1 is an enzyme encoded by the PLK1 (polo-like kinase 1) gene. It is highly expressed during mitosis and elevated levels are found in many different types of cancer. Depletion of this protein in cancer cells dramatically inhibited cell proliferation and induced apoptosis.
The report 'SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2018' outlays comprehensive information on the Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colorectal Cancer, Esophageal Cancer, Leukemias, Myelodysplastic Syndrome, Ovarian Cancer, Pancreatic Cancer, Skin Cancer, Anal Cancer, Breast Cancer, Cervical Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Human Papillomavirus (HPV) Associated Cancer, Juvenile Myelomonocytic Leukemia (JMML), Lung Cancer, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Penile Cancer, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sarcomas, Small-Cell Lung Cancer, Solid Tumor, Squamous Cell Carcinoma and Squamous Non-Small Cell Lung Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2018'; Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Serine/threonine-protein kinase PLK1 is an enzyme encoded by the PLK1 (polo-like kinase 1) gene. It is highly expressed during mitosis and elevated levels are found in many different types of cancer. Depletion of this protein in cancer cells dramatically inhibited cell proliferation and induced apoptosis.
The report 'SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2018' outlays comprehensive information on the Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colorectal Cancer, Esophageal Cancer, Leukemias, Myelodysplastic Syndrome, Ovarian Cancer, Pancreatic Cancer, Skin Cancer, Anal Cancer, Breast Cancer, Cervical Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Human Papillomavirus (HPV) Associated Cancer, Juvenile Myelomonocytic Leukemia (JMML), Lung Cancer, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Penile Cancer, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sarcomas, Small-Cell Lung Cancer, Solid Tumor, Squamous Cell Carcinoma and Squamous Non-Small Cell Lung Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21)
- The report reviews Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics and enlists all their major and minor projects
- The report assesses Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Overview
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Companies Involved in Therapeutics Development
Adhera Therapeutics
Boehringer Ingelheim GmbH
Cyclacel Pharmaceuticals Inc
Onconova Therapeutics Inc
PhoreMost Ltd
Takeda Pharmaceutical Co Ltd
Trovagene Inc
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Drug Profiles
Antisense Oligonucleotide to Target MIR34 and PLK1 for Pancreatic Ductal Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYC-140 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LS-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onvansertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rigosertib sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PLK1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PLK1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
volasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Dormant Products
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Discontinued Products
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Product Development Milestones
Featured News & Press Releases
Nov 05, 2018: Onconova announces four presentations from Rigosertib clinical trials in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting & Exposition
Oct 24, 2018: New patent claims strengthen patent estate revenue aligns with Onvansertib clinical development and biomarker strategy in AML
Oct 18, 2018: Trovagene to provide update on Onvansertib clinical development program on October 24, 2018
Oct 17, 2018: Onconova Therapeutics Announces Issuance of a New U.S. Patent for Rigosertib
Sep 27, 2018: Trovagene Announces Completion of Dosing Cohort of Patients Treated with Onvansertib in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial
Sep 05, 2018: Trovagene announces predictive clinical biomarker approach to identify Acute Myeloid Leukemia patients most likely to respond to Onvansertib
Aug 29, 2018: Trovagene announces European Commission grants orphan drug designation to Onvansertib (PCM-075) for treatment of acute myeloid leukemia in Europe
Aug 21, 2018: Onconova Therapeutics announces plan for expanding Rigosertib clinical trials for patients with Myelodysplastic Syndromes to South America with Pint Pharma
Aug 16, 2018: Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial
Aug 15, 2018: Trovagene Receives USAN Approval for Onvansertib as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075
Aug 01, 2018: Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Investigational Cancer Drug
Jun 27, 2018: Trovagene Announces Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of PCM-075 in Combination with Cytarabine or Decitabine in Patients with Relapsed or Refractory AML
Jun 21, 2018: Trovagene starts enrolment in Phase ll trial of PCM-075 and Zytiga
Jun 15, 2018: Trovagene Announces Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial
Jun 07, 2018: Onconova Therapeutics Announces Presentation at the 23rd Congress of the European Hematology Association
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Overview
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Companies Involved in Therapeutics Development
Adhera Therapeutics
Boehringer Ingelheim GmbH
Cyclacel Pharmaceuticals Inc
Onconova Therapeutics Inc
PhoreMost Ltd
Takeda Pharmaceutical Co Ltd
Trovagene Inc
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Drug Profiles
Antisense Oligonucleotide to Target MIR34 and PLK1 for Pancreatic Ductal Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYC-140 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LS-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onvansertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rigosertib sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PLK1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PLK1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
volasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Dormant Products
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Discontinued Products
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Product Development Milestones
Featured News & Press Releases
Nov 05, 2018: Onconova announces four presentations from Rigosertib clinical trials in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting & Exposition
Oct 24, 2018: New patent claims strengthen patent estate revenue aligns with Onvansertib clinical development and biomarker strategy in AML
Oct 18, 2018: Trovagene to provide update on Onvansertib clinical development program on October 24, 2018
Oct 17, 2018: Onconova Therapeutics Announces Issuance of a New U.S. Patent for Rigosertib
Sep 27, 2018: Trovagene Announces Completion of Dosing Cohort of Patients Treated with Onvansertib in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial
Sep 05, 2018: Trovagene announces predictive clinical biomarker approach to identify Acute Myeloid Leukemia patients most likely to respond to Onvansertib
Aug 29, 2018: Trovagene announces European Commission grants orphan drug designation to Onvansertib (PCM-075) for treatment of acute myeloid leukemia in Europe
Aug 21, 2018: Onconova Therapeutics announces plan for expanding Rigosertib clinical trials for patients with Myelodysplastic Syndromes to South America with Pint Pharma
Aug 16, 2018: Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial
Aug 15, 2018: Trovagene Receives USAN Approval for Onvansertib as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075
Aug 01, 2018: Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Investigational Cancer Drug
Jun 27, 2018: Trovagene Announces Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of PCM-075 in Combination with Cytarabine or Decitabine in Patients with Relapsed or Refractory AML
Jun 21, 2018: Trovagene starts enrolment in Phase ll trial of PCM-075 and Zytiga
Jun 15, 2018: Trovagene Announces Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial
Jun 07, 2018: Onconova Therapeutics Announces Presentation at the 23rd Congress of the European Hematology Association
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Adhera Therapeutics, H2 2018
Pipeline by Boehringer Ingelheim GmbH, H2 2018
Pipeline by Cyclacel Pharmaceuticals Inc, H2 2018
Pipeline by Onconova Therapeutics Inc, H2 2018
Pipeline by PhoreMost Ltd, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pipeline by Trovagene Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Dormant Products, H2 2018 (Contd.3), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Adhera Therapeutics, H2 2018
Pipeline by Boehringer Ingelheim GmbH, H2 2018
Pipeline by Cyclacel Pharmaceuticals Inc, H2 2018
Pipeline by Onconova Therapeutics Inc, H2 2018
Pipeline by PhoreMost Ltd, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pipeline by Trovagene Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Dormant Products, H2 2018 (Contd.3), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Adhera Therapeutics
Boehringer Ingelheim GmbH
Cyclacel Pharmaceuticals Inc
Onconova Therapeutics Inc
PhoreMost Ltd
Takeda Pharmaceutical Co Ltd
Trovagene Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Adhera Therapeutics
Boehringer Ingelheim GmbH
Cyclacel Pharmaceuticals Inc
Onconova Therapeutics Inc
PhoreMost Ltd
Takeda Pharmaceutical Co Ltd
Trovagene Inc
